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1. Background
The importance of biomarkers in disease screening, diagnosis, and risk prediction has been generally
recognized. A well-established criterion for biomarker selection is classification accuracy, commonly
characterized by the Receiver Operating Characteristic (ROC) curve and its summary measures.
However, classification is not always the major focus. Oftentimes we use biomarkers to calculate
the risk of an outcome. Recently, there has been increasing awareness that the ROC curve is not
the most relevant tool for assessing a biomarker whose purpose is risk prediction (Gail and Pfeiffer,
2005; Huang et al., 2007; Pepe et al., 2007; Cook, 2007). On the one hand, the ROC curve does
not display risk which is of primary interest to patients and clinicians. On the other hand, criteria
relating to classification oftentimes can be too stringent for evaluation of a risk prediction marker.
To characterize the predictive capacity of a continuous marker or risk model, Huang et al. (2007)
proposed a new graphical tool, the predictiveness curve, to display the population distribution of
disease risk predicted by the particular marker or risk model.
Let D denote a binary outcome that we term disease here, D = 1 for diseased and D = 0 for
non-diseased. Let Y denote a vector of predictors of interest and Risk(Y ) = P (D = 1|Y ) denote
the risk calculated on the basis of Y . The predictiveness curve for Y is the curve R(v) vs v for
v ∈ (0, 1), where R(v) is the vth percentile of Risk. The inverse function
R−1(p) = P (Risk ≤ p),
is the proportion of the population with risks less than or equal to p. In other words R−1(p) is the
population cumulative distribution function of risk. An appealing property of the predictiveness
curve is that it provides a common meaningful scale for making comparisons between markers or
risk models that may not be comparable on their original scales. Comparisons might be based on
R(v), the risk percentiles. A better risk prediction marker tends to have larger variability in R(v).
A clinically compelling comparison is based on R−1(p). Suppose there exists a low risk threshold pL
and/or a high risk threshold pH which are agreed upon apriori such that the decision for treatment
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is recommendation for or against if the estimated risk for a patient is above pH or below pL. A
marker or risk model is preferable to another if it categorizes more people into the low and high
risk ranges where decisions are easy to make and leaves fewer subjects in the equivocal risk range.
That is, we hope to identify markers that have large values of R−1(pL) and 1−R−1(pH) and small
values of R−1(pH)− R−1(pL).
Figure 1 displays ROC and predictiveness curves for PSA and PSA velocity as classification or
risk prediction markers for prostate cancer. Details of the data will be discussed in Section 4. The
ROC curves shown in Figure 1(a) suggest that PSA has better classification accuracy than PSA
velocity. The corresponding predictiveness curves are shown in Figure 1(b). We see for example
that at the 90th percentile the risk is 0.372 for PSA but only 0.295 for PSA velocity suggesting PSA
is a better marker of high risk than PSA velocity. PSA is also a better marker of low risk. The 10th
percentile of risk is 0.145 according to PSA velocity but much lower based on PSA, 0.091. We can
also consider the inverse function taking pH = 0.29 and pL = 0.10. PSA is predictive of low risk in
R−1(0.10) = 13.6% of the population, more than 3.0%, the proportion identified with PSA velocity.
PSA also identifies more people at high risk than does PSA velocity with 1− R−1(0.29) = 25.5%
and 11.1% respectively. Less patients are categorized into the equivocal risk range according to
PSA (60.9%) than PSA velocity (85.9%).
Semi-parametric estimators for making inference about the curve and for making pointwise
comparisons between two curves from a cohort study have been developed by Huang et al. (2007).
Since case-control studies are often performed in the early phases of biomarker development (Pepe
et al., 2001), it is important to estimate the predictiveness of continuous biomarkers in studies
that use this type of design as well. When the disease of interest is rare in the population, using
a case-control sampling to oversample cases can be more efficient than simple random sampling
from the population. In this paper, we consider estimation of the predictiveness curve from a
case-control study based on modeling a parametric ROC curve, assuming the disease prevalence
is known apriori. The idea behind this is the one-to-one relationship between the predictiveness
2
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Figure 1. ROC curves and Predictiveness curves for two markers of prostate cancer estimated
from the PCPT cohort data.
curve and the ROC curve.
2. Relationship between the Predictiveness Curve and the ROC Curve
Here we focus on the scenario of a single continuous marker. Note the marker may be a predefined
combination of predictors such as the Framingham risk score. Denote Y , YD , and YD¯ as the marker
measurement in the general, diseased, and non-diseased populations respectively. Let F , FD, and
FD¯ be the corresponding distribution functions and let f , fD, and fD¯ be the density functions. We
assume the disease prevalence ρ = P (D = 1) is known and that the risk of disease P (D = 1|Y ) is
monotone increasing in Y .
Under this monotone increasing risk assumption, we have R(v) = P{D = 1|Y = F−1(v)}. The
following theorem characterizes the one-to-one relationship between the predictiveness curve and
the ROC curve.
Theorem 1
Suppose YD and YD¯ have absolutely continuous distribution functions and P (D = 1|Y ) is
monotone increasing in Y . Further suppose the support of YD¯ covers the support of YD . Then
3
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R(v) vs v can be represented as
ρROC′(t)
ρROC′(t) + (1− ρ) vs 1− (1− ρ)t− ρROC(t), t ∈ (0, 1), (1)
where the ROC curve at false positive rate t is ROC(t), and ROC′(t) is its derivative with respect
to t.
Proof
For v ∈ (0, 1), let y = F−1(v). Suppose FD¯(y) = 1− t, since y is within the support of YD¯, we
have y = F−1
D¯
(1− t) trivially. Let LR denote the likelihood ratio function: LR(y) = fD(y)/fD¯(y).
We have
v = F (y) = (1− ρ)FD¯(y) + ρFD(y)
= (1− ρ)(1− t) + ρFD(F−1D¯ (1− t))
= (1− ρ)(1− t) + ρ{1− ROC(t)}
= 1− (1− ρ)t− ρROC(t).
Moreover,
R(v) = P{D = 1|Y = y}
=
ρLR(y)
ρLR(y) + (1− ρ)
=
ρLR{F−1
D¯
(1− t)}
ρLR{F−1
D¯
(1− t)}+ (1− ρ)
=
ρROC′(t)
ρROC′(t) + (1− ρ) .
The last equality holds since LR{F−1
D¯
(1 − t)} = ROC′(t) (Pepe, 2003). Note the result can be
generalized to the scenario when the upper bound of the support for YD is larger than the upper
bound of the support for YD¯. We omit the details because it is not relevant for the method discussed
4
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in this paper.
Theorem 1 has implications for estimating the predictiveness curve from a case-control sample
with nD cases and nD¯ controls. We can estimate a smooth ROC curve first and then derive the
corresponding predictiveness curve based on (1). This is an appealing procedure for the following
reasons: (i) The fact that the ROC curve can be estimated only from ranked data implies that
methods for deriving the predictiveness curve from a rank-based ROC curve estimate also only
depend on ranks. This contrasts with previous methods proposed (Huang et al., 2007). (ii) Esti-
mation of the ROC curve is a well studied problem. There are a wide variety of methods available.
(iii) It is natural to estimate the ROC curve from a case-control study since sensitivity and speci-
ficity are defined conditional on disease status. (iv) The area under the estimated predictiveness
curve that is derived from an estimated ROC curve is always equal to ρ, as shown below. This is
a fundamental property of the predictiveness curve since
∫ 1
0 R(v)dv = E(Risk) = E(D) = ρ.
∫ 1
0
R(v)dv
=
∫ t=0
t=1
ρROC′(t)
ρROC′(t) + (1− ρ)d {1− (1− ρ)t− ρROC(t)}
= −
∫ t=0
t=1
ρROC′(t)
ρROC′(t) + (1− ρ)
{
(1− ρ) + ρROC′(t)}dt
= ρ
∫ t=1
t=0
ROC′(t)dt
= ρ {ROC(1)− ROC(0)}
= ρ (2)
This result holds for the ROC curve based on a continuous marker as well as the ROC curve
constructed from a discrete marker which has finite derivative everywhere (details omitted). When
we compare two markers with respect to the steepness of their estimated predictiveness curves, it
facilitates visual comparisons when the estimated curves have the same area under the curve.
Approaches to estimate an ROC curve vary along a spectrum regarding assumptions made. At
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the one extreme, we can model the marker distributions within cases and controls parametrically
and estimate the corresponding ROC curve. For example Wieand et al. (1989) modeled YD and
YD¯ as normally distributed. At the other extreme, an ROC curve can be estimated completely
nonparametrically using empirical estimators for FD and FD¯ (Greenhouse and Mantel, 1950; Hsieh
and Turnbull, 1996). A method in-between is to assume a parametric model for the ROC curve
without enforcing any parametric distributional assumptions on marker measures. This semi-
parametric approach is more efficient than the nonparametric approach, yet more robust than
modeling the marker distributions parametrically. A review of these approaches will be given later.
Before we start exploring different parametric ROC models, we note that the assumption that
P (D = 1|Y = y) is increasing in y implies that LR(y) is increasing in y which in turn implies that
ROC′(t) is decreasing in t. That is, a monotone increasing risk assumption implies concavity of
the corresponding ROC curve. Therefore, we prefer methods that lead to concave estimates of the
ROC curves. Note that concavity has always been a desirable property for an ROC curve because
it guarantees that the ROC curve will never cross the 45◦ “guessing line” (Dorfman et al., 1996)
and because it is a property of the optimal ROC curve for decision rules based on y (McIntosh and
Pepe, 2002).
3. Parametric ROC Models
3.1 The Binormal ROC Curve
The most widely used parametric ROC model is the binormal ROC curve. It assumes that
there exists a common monotone transformation h, which transforms the marker distributions in
both cases and controls to normality. Suppose h(YD¯) ∼ N(µD¯, σ2D¯), h(YD) ∼ N(µD, σ2D), the
corresponding ROC curve is
ROC(t) = Φ{a+ bΦ−1(t)},
where a = (µD − µD¯) /σD and b = σD¯/σD. Many algorithms have been proposed to fit the binormal
ROC curve. Moreover, the binormal assumption is thought to fit many real datasets (Hanley, 1988).
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However, a problem with using the binormal ROC model is that it is not concave in (0, 1) unless
b = 1 (i.e. the normal distributions for cases and controls have the same variance). This can be
recognized from the quadratic form of the derivative of the binormal ROC curve,
ROC′(t) =
bφ{a+ bΦ−1(t)}
φ{Φ−1(t)} = C
+ exp
[
−1
2
(b2 − 1)
{
Φ−1(t) +
ab
b2 − 1
}2]
, (3)
where C+ is some positive constant.
Thus, if we assume the risk function is monotone increasing as Y increases, the binormal model
is not a suitable model for the ROC curve unless we assume σD = σD¯.
3.2 Concave Parametric ROC Models
Two published parametric models for concave ROC curves are the bigamma and bilomax mod-
els. The bigamma ROC curve (Dorfman et al., 1996) assumes there exists a common monotone
transformation that transforms the distributions of YD and YD¯ into gamma distributions with the
same shape parameter, an extension to the one-parameter exponential family of England (1988).
The use of this ROC model is hindered by the fact that the ROC function cannot be written down
in closed-form. The bilomax ROC curve proposed by Campbell and Ratnaparkhi (1993) assumes
the existence of a monotone transformation h such that the distributions of h(YD¯) and h(YD) are
lomax or type II Pareto (Lomax, 1954). That is,
fD¯{h(YD¯)} =
b1k1
{1 + b1h(YD¯)}k1+1
, b1 > 0, k1 > 0,
fD{h(YD)} = b2k2{1 + b2h(YD)}k2+1 , b2 > 0, k2 > 0.
where b1, b2 and k1, k2 are scale and shape parameters respectively. The corresponding ROC curve
has an explicit form:
ROC(t) =
{
1 +
b2
b1
(
t−1/k1 − 1
)}−k2
≡
{
1 + b
(
t−1/k1 − 1
)}−k2
.
7
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This three-parameter bilomax ROC curve is concave if b = b2/b1 < 1 and k2 ≤ k1.
For estimation of a whole predictiveness curve, we choose estimation of the bilomax ROC
curve as an intermediate step. In practice, the likelihood based on the three-parameter model
can be very flat leading to numerical difficulties in maximization (Campbell and Ratnaparkhi,
1993). Hence we use a two-parameter bilomax ROC model that restricts k1 = k2 = k. This
simplifies numerical fitting procedures considerably with only a minor loss in flexibility. Under
the two-parameter bilomax ROC model ROC(t) =
{
1 + b
(
t−1/k − 1)}−k , we have ROC′(t) =
bt−1/k−1
{
1 + b(t−1/k−1)
}−k−1
.
3.3 Estimation
Denote by ROCθ(t), t ∈ (0, 1), the parametric ROC curve with parameter θ. Define
G(θ, t) =
ρROC′θ(t)
ρROC′θ(t) + (1− ρ)
and
H(θ, t) = 1− (1− ρ)t− ρROCθ(t).
Let
G−1(θ, p) = inf {t : G(θ, t) ≤ p}
and
H−1(θ, v) = {t : H(θ, t) = v}.
We can estimate θ using algorithms described below and denote its estimation by θˆ. Estimators of
the corresponding predictiveness curve and its inverse are
Rˆ(v) = G
{
θˆ, H−1(θˆ, v)
}
for v ∈ (0, 1),
Rˆ−1(p) = H
{
θˆ, G−1(θˆ, p)
}
for p ∈ {R(v) : v ∈ (0, 1)} .
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In practice, oftentimes there does not exist a closed-form for H−1(·) or G−1(·) and numerical
methods need to be implemented to calculate Rˆ(v) and Rˆ−1(p).
There are many existing semi-parametric approaches we can use to estimate θ for a whole
ROC curve. Metz et al. (1998) proposed grouping continuous data and estimating the parameters
based on the Dorfman and Alf maximum-likelihood algorithm for ordinal data (Dorfman and Alf,
1969). Hsieh and Turnbull (1996) developed a generalized least squares method to fit a parametric
ROC curve to discretized continuous data. Pepe (2000) and Alonzo and Pepe (2002) proposed
a distribution-free ROC-GLM procedure. Zou and Hall (2000) developed maximum likelihood
rank-based estimator as solution to the score equations derived from the likelihood function of the
order statistics. Pepe and Cai (2004) maximized the pseudolikelihood based on the standardized
marker value. Cai and Moskowitz (2004) developed a maximum profile likelihood approach which
provides a fully efficient parameter estimate. These semi-parametric approaches have the advantage
of being rank-based. We can also model the marker distributions parametrically (Wieand et al.,
1989), the corresponding ROC curve and the predictiveness curve estimators, however, do not have
this rank-invariance property.
3.4 Modeling a Portion of the Predictiveness Curve
3.4.1 Boundary Problems In fitting a parametric risk model to data, we assume the model
holds over the observed range of the data. In contrast, for the parametric-ROC-model, the
parametric form of ROC′θ(t) is assumed to hold as t → 0 and t → 1. The heavy reliance of
limt→0ROC′θ(t) and limt→1ROC
′
θ(t) on the parametric model causes a lack of flexibility in the
estimated predictiveness curve, especially at the boundary. For example, with a binormal ROC
model, limt→1ROC′(t) = 0 or ∞, which implies Risk(y) = 0 or 1 as y → ∞ and consequently
R(1) = 0 or 1, which may not be reasonable in practice.
As shown in Table 1, when a binormal ROC model is enforced, the boundary of the predictive-
ness curve has value either 0 or 1, completely determined by the parameter b, the ratio of standard
deviation between the latent case and control marker distributions. When a bilomax ROC model
9
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Table 1
Properties of parametric ROC models and the corresponding predictiveness curves.
limROC′(t) Implications for limR(v)
Binormal ROC(t) = Φ{a+ bΦ−1(t)}
b < 1
limt→1ROC′(t)→∞ limv→0R(v) = 1
limt→0ROC′(t)→∞ limv→1R(v) = 1
b > 1
limt→1ROC′(t)→ 0 limv→0R(v) = 0
limt→0ROC′(t)→ 0 limv→1R(v) = 0
b = 1
limt→1ROC′(t)→ 0 limv→0R(v) = 0
limt→0ROC′(t)→∞ limv→1R(v) = 1
Bilomax ROC(t) =
{
1 + b
(
t−1/k1 − 1)}−k2
k2 < k1
limt→1ROC′(t)→ bk2/k1 limv→0R(v) = ρρ+(1−ρ)k1/(bk2)
limt→0ROC′(t)→∞ limv→1R(v) = 1
k2 = k1 = k
limt→1ROC′(t)→ b limv→0R(v) = ρρ+(1−ρ)/b
limt→0ROC′(t)→ 1/bk limv→1R(v) = ρρ+(1−ρ)bk
is assumed, there is more flexibility compared to a binormal ROC model at the boundary of the
predictiveness curve estimate. But still the values of Rˆ(v) as v approaches 0 and 1 depend entirely
on the parameter estimates of the corresponding ROC curve.
We propose to modify the approach described in Section 3.3 such that the predictiveness curve
estimator is more data-dependent at the boundary without losing the rank-invariance property. In
particular we consider modelling a portion of the ROC curve.
3.4.2 The Partial Predictiveness Curve Heretofore our interest was in estimating the predic-
tiveness curve over the whole domain v ∈ (0, 1) by first estimating a parametric ROC model over its
whole domain t ∈ (0, 1). However, to evaluate a marker for its risk prediction capability, sometimes
we do not need the whole predictiveness curve if only risks within a particular range are of primary
interest. We can instead examine a segment of the predictiveness curve covering those points of
10
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major concern. To derive this “partial predictiveness curve” using a ROC curve based strategy,
only a portion of the ROC curve needs to be modeled.
Researchers in the field of diagnostic test evaluation have long been interested in the partial
ROC curve. For example, in screening studies, it is important to minimize the unnecessary cost due
to false positive test results, hence the region of the ROC curve corresponding to low FPF is most
relevant. If the purpose of the study is disease diagnosis, it is critical not to miss detecting subjects
with disease, and hence the part of the ROC curve corresponding to high TPF is of primary interest.
Modeling a partial ROC curve and the area under it has been proposed and studied (McClish, 1989;
Thompson and Zucchini, 1989; Jiang et al., 1996; Dodd and Pepe, 2003; Pepe and Cai, 2004).
Interestingly, when concavity is required only over a certain portion of the ROC curve, paramet-
ric ROC models which are not concave in the whole range may be employed. Consider the classic
binormal ROC curve, ROC(t) = Φ
{
a+ bΦ−1(t)
}
, whose derivative is shown in (3). Consider the
following two scenarios.
(i) If 0 < b < 1, ROC′(t) increases as
{
Φ−1(t) + ab/(b2− 1)}2 increases. Thus for ROC′(t) to
be monotone decreasing, we need to have
Φ−1(t) <
−ab
b2 − 1 ⇐⇒ t < Φ
( −ab
b2 − 1
)
⇐⇒ a > 1− b
2
b
Φ−1(t).
That is, a portion of the ROC curve with small FPF could be modeled to be concave.
(ii) If b > 1, ROC′(t) increases as
{
Φ−1(t) + ab/(b2− 1)}2 decreases. Thus for ROC′(t) to be
monotone decreasing, we need to have
Φ−1(t) >
−ab
b2 − 1 ⇐⇒ t > Φ
( −ab
b2 − 1
)
⇐⇒ a > 1− b
2
b
Φ−1(t).
That is, a portion of the ROC curve with large TPF could be modeled to be concave.
We can impose this restriction during estimation to guarantee concavity of the partial binormal
ROC curve over the range of interest. Suppose concavity is required for t ∈ (t0, t1), we can fit the
11
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ROC model with the restriction on parameter estimates (a, b):
a >
1− b2
b
Φ−1(t0) & a >
1− b2
b
Φ−1(t1).
3.5 Asymptotic Theory for the Estimator of the Predictiveness Curve Derived from a Parametric
ROC Model
Suppose Rˆ(v) and Rˆ−1(p) are estimators of R(v) and R−1(p) based on either modeling a whole
range or a portion of the predictiveness curve. We assume the following conditions hold for asymp-
totic theory.
Assumptions
(i)
√
n
(
θˆ − θ
)
d→ N (0,Σ(θ)).
(ii) ROCθ(t) is differentiable with respect to θ and t.
(iii) G(θ, t) is differentiable with respect to θ and t with derivatives g1 and g2.
(iv) H−1(θ, v) is differentiable with respect to θ.
(v) G−1(θ, p) is differentiable with respect to θ.
Theorem 2
√
n
{
Rˆ(v)− R(v)
}
d→ N (0, σ2(v)) ,
where
σ2(v) =
[
g1
{
θ,H−1(θ, v)
}
+ g2
{
θ,H−1(θ, v)
}(∂H−1(θ, v)
∂θ
)]T
Σ(θ)[
g1
{
θ,H−1(θ, v)
}
+ g2
{
θ,H−1(θ, v)
}(∂H−1(θ, v)
∂θ
)]
.
Theorem 3
√
n
{
Rˆ−1(p)−R−1(p)
}
d→ N (0, τ2(p)) ,
12
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where
τ2(p) =
(
∂H
{
θ, G−1(θ, p)
}
∂θ
)T
Σ(θ)
(
∂H
{
θ, G−1(θ, p)
}
∂θ
)
,
where
∂H
{
θ, G−1(θ, p)
}
∂θ
= ρ
∂ROCθ
{
G−1(θ, p)
}
∂θ
+
[
1− ρ+ ρROC′θ{G−1(θ, p)}
] ∂G−1(θ, p)
∂θ
.
Observe that σ2(v) = {∂R(v)/∂v}2 τ2(p) = [g2 {θ,H−1(θ, v)}∂H−1(θ, v)/∂v]2 τ2(p) for p =
R(v). Theorems 2 and 3 follow directly from the continuous mapping theorem and chain rule. In
practice, due to the lack of closed-forms for H−1(·) and G−1(·), numerical differentiation methods
are needed for calculation of their derivatives, in order to estimate the variances of Rˆ(v) and Rˆ−1(p).
4. Markers for Prostate Cancer
The Prostate Cancer Prevention Trial (PCPT) was a randomized prospective study of men with
PSA < 3.0 ng/mL and aged 55+ years who were followed up for 7 years with annual PSA measure-
ments. A biopsy was recommended for all men either during or at the end of the study. Thompson
et al. (2006) identified 5519 men on the placebo arm of the trial who had undergone prostate biopsy
and had a PSA and digital rectal exam (DRE) during the year prior to biopsy and at least 2 PSA
values from the 3 years prior to biopsy. The risk of finding prostate cancer in the biopsy was eval-
uated as a function of PSA, PSA velocity and several other variables including age, family history,
DRE and prior prostate biopsy. The concept is that in the future a man may use his calculated
risk to decide whether or not to have a biopsy procedure performed. We use this study cohort as
our population of interest and illustrate estimation of the predictiveness curve using a case-control
subset from the cohort. 250 cases and 250 controls are randomly sampled, from which we compare
PSA and PSA velocity as predictors of prostate cancer risk. 21.9% of men were found to have
prostate cancer in the original cohort. This number is treated as the “known” prevalence in our
13
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Figure 2. ROC curve estimates from the PCPT data: (a) PSA, (b) PSA velocity.
analysis.
We fit a two-parameter bilomax ROC curve, a partial bilomax ROC curve with t ∈ (0.05, 0.91),
and a partial binormal ROC curve with t ∈ (0.05, 0.91) to the case-control data, from which the
predictiveness curves are derived. We modified the maximum profile likelihood method for fitting
a binormal ROC curve (Cai and Moskowitz, 2004) to fit the bilomax ROC curve. The placement-
value-based pseudolikelihood approach (Pepe and Cai, 2004) is used to fit the partial bilomax and
binormal ROC curves. The estimated ROC curves for PSA and PSA velocity are displayed in
Figure 2. Also displayed are the empirical ROC curves (Obuchowski, 2003) estimated from the
case-control sample. The parametric ROC curve estimates in general agree fairly well with the
empirical ROC curves. The difference between the whole and partial bilomax ROC curves appears
to be smaller compared to the differences between them and the partial binormal ROC curve.
PSA appears to have much better classification accuracy than PSA velocity for diagnosing prostate
cancer.
Figure 3 displays the corresponding predictiveness curves estimated from the case-control sample
for PSA and PSA velocity as well as the empirical predictiveness curve estimate. The empirical
14
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predictiveness curve is generated in the following way. The observations are partitioned into 10
groups according to cutpoints y1, y2, . . ., y9. Let YDj be the jth case and let YD¯i be the i
th control.
Let y10 = 1, for k ∈ {1, . . . , 10}, we calculate
vk = ρ
1
nD
nD∑
j=1
I(YDj ≤ yk) + (1− ρ) 1
nD¯
nD¯∑
i=1
I(YD¯i ≤ yk).
We then calculate P (D = 1|k, sampled), the average risk within the kth group in the case-control
sample, using sample mean of D. The population risk within kth group, P (D = 1|k) is calculated
based on the Bayes theorem
P (D = 1|k)
1− P (D = 1|k) =
P (D = 1|k, sampled)
1− P (D = 1|k, sampled)
nD¯
nD
1− ρ
ρ
.
The cutpoints are chosen such that vk is the smallest number larger than or equal to k/10. Let v0 =
0, the empirical predictiveness curve is generated as R(v) = P (D = 1|k) for v ∈ (vk−1, vk]. Again,
the predictiveness curves derived from parametric ROC models do not appear to be dramatically
different from the empirical curve. The predictiveness curve derived from the whole bilomax ROC
curve is very similar to that derived from the partial bilomax ROC curve whereas the predictiveness
curve derived from the partial binormal ROC curve looks much more different. In general, the curve
for PSA velocity is shallower, indicating that it is a poorer marker of risk for prostate cancer. Figure
4 shows the predictiveness curves for PSA and PSA velocity derived from the partial bilomax and
binormal ROC curves with pointwise 95% percentile bootstrap confidence intervals. Comparing
Figure 4(a) with Figure 4(b), we see that assuming different parametric ROC models has a big
impact on both the predictiveness curve estimates and their variances, even if there does not
appear to be a dramatic difference between the corresponding ROC curves (Figure 2(a) and (b)).
This is consistent with our previous argument about the distinction between risk prediction and
classification: one risk model can make a big difference compared to another in terms of risk
prediction without having much impact in terms of classification.
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Figure 3. Predictiveness curves for two markers of prostate cancer estimated from the PCPT
cohort and case-control data: (a) PSA, (b) PSA velocity.
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Figure 4. Predictiveness curves for two markers of prostate cancer estimated from the PCPT
case-control data (solid lines) and their pointwise 95% percentile bootstrap confidence intervals
(dashed lines): (a) bilomax, (b) partial binormal.
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Table 2
Estimation of predictiveness curves for PSA and PSA velocity using case-control data from the
PCPT study. Estimation are based on parametric ROC models. P-values are based on the
comparison between PSA and PSA velocity using bootstrap variance estimates.
Model PSA PSA Velocity p-value
Est 95% CI Est 95% CI
Partial Bilomax R(0.1) 7.0 (4.2, 10.2) 9.3 (5.5, 15.1) 0.378
R(0.9) 42.7 (35.9, 48.0) 29.1 (25.7, 36.4) < 0.001
R−1(0.10) 25.2 (11.5, 34.6) 11.9 (8.0, 21.1) 0.022
1− R−1(0.29) 31.5 (23.2, 38.3) 18.6 (12.4, 42.2) 0.122
R−1(0.29)−R−1(0.10) 43.3 (30.8, 61.8) 69.5 (36.0, 72.0) 0.020
Partial Binormal R(0.1) 6.2 (3.1, 11.0) 10.5 (7.2, 15.7) 0.107
R(0.9) 38.9 (33.0, 45.6) 30.8 (27.4, 36.5) 0.022
R−1(0.10) 21.6 (10.5, 31.3) 8.8 (8.1, 19.1) 0.018
1− R−1(0.29) 24.9 (20.5, 26.9) 15.4 (8.2, 22.6) 0.010
R−1(0.29)−R−1(0.10) 53.5 (42.6, 66.3) 75.8 (59.7, 81.1) 0.002
Table 2 presents estimates of R(0.1) and R(0.9). Also shown are proportions allocated into the
low, high, and equivocal risk ranges, given a low risk threshold 11% and a high risk threshold 29%.
For example, based on the partial bilomax model, the 90th percentile of risk is 0.291 according to
PSA velocity while it is higher, 0.427, according to the absolute most recent PSA measurement
(p < 0.001). At the low end of the scale, the 10th percentiles of risk based on PSA velocity and
PSA are 0.07 and 0.093 respectively (p = 0.378). According to PSA velocity 14.5% of men can
be classified as having risk below 11% while far more, 29.1%, qualify as low risk when using most
recent PSA as the marker (p = 0.009). In addition, a greater fraction are found to have risks above
29% with PSA than with PSA velocity, 31.5% vs 18.6% (p = 0.122). Less men are categorized
into the equivocal risk zone by PSA 39.4% than by PSA velocity 66.9% (p = 0.014). These results
suggest that PSA performs better for stratifying risk of prostate cancer compared to PSA velocity.
Inference based on the partial binormal ROC model is similar.
Finally, note that the parametric ROC curve methodology can be applied to a cohort study
as well by plugging in the sample prevalence. Table 3 shows the results of predictiveness curves
estimated using the entire PCPT cohort. We compare the bilomax ROC model based approach
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Table 3
Estimation of predictiveness curves for PSA and PSA velocity using data for the entire PCPT
cohort. The semi-parametric method of Huang et al. (2007) is compared with parametric ROC
based method. P-values are based on the comparison between PSA and PSA velocity using
bootstrap variance estimates.
Model PSA PSA Velocity p-value
Est SE Est SE
Semiparametric R(0.1) 9.0 0.0067 14.5 0.0077 < 0.001
R(0.9) 37.2 0.0092 29.5 0.0078 < 0.001
R−1(0.10) 13.6 0.020 3.0 0.0083 < 0.001
1− R−1(0.29) 25.5 0.0099 11.1 0.018 < 0.001
R−1(0.29)−R−1(0.10) 60.9 0.027 85.9 0.026 < 0.001
Bilomax R(0.1) 9.2 0.0062 12.7 0.0068 < 0.001
R(0.9) 39.5 0.011 33.8 0.010 < 0.001
R−1(0.10) 14.6 0.033 0 0.0059 < 0.001
1− R−1(0.29) 28.4 0.017 22.3 0.018 0.007
R−1(0.29)−R−1(0.10) 57.0 0.048 77.7 0.021 < 0.001
and the semi-parametric method developed in Huang et al. (2007) assuming logit{P (D = 1|Y )} =
β0 + β1Y (β2) where Y (λ) = (Y λ − 1)/λ when λ 6= 0 and Y (λ) = logY when λ = 0. The results are
in close agreement. Moreover, standard errors of estimators based on the two methods are similar
in magnitude. This suggests that by applying the case-control methods presented here to cohort
data, efficiency is not lost relative to existing methods that only apply to cohort studies.
5. Discussion
Classification accuracy is usually considered to be an intrinsic property of a marker because it
does not depend on the population-specific disease prevalence. Predictiveness, on the other hand,
integrates classification accuracy and disease prevalence (Pepe et al., 2007) and characterizes the
risk prediction ability of the marker in a particular population. In this paper, we show the one-to-
one relationship between the ROC curve and the predictiveness curve when disease prevalence is
known. The latter has been proposed as a graphical tool for evaluating a continuous risk prediction
marker. We developed methodology for estimating the predictiveness curve based on a parametric
ROC model from a case-control study design. The idea of estimating an ROC curve first seems
18
http://biostats.bepress.com/uwbiostat/paper318
very natural in this retrospective setting considering that criteria for classification accuracy are
defined conditional on disease status. The availability of a wide variety of methods for estimating
a parametric ROC curve makes this approach even more appealing.
The main limitation of assuming a parametric ROC model, however, is lack of flexibility in
the predictiveness curve estimator, especially at the boundary. Estimating a partial predictiveness
curve from a portion of the ROC curve holds promise for resolving this issue. At the same time, it
allows use of the most popular parametric ROC model, the binormal ROC model, which may not
be concave in the whole range of FPF but can be restricted to be concave in certain regions.
Our methods can be used to compare the risk prediction capacities of different markers as we
have shown with the prostate cancer example. Some extensions should be considered. For example,
when predictiveness curves in subpopulations are of interest, we can estimate the covariate-specific
ROC curve using existing ROC regression methods and derive the corresponding covariate-specific
predictiveness curve by plugging in the disease prevalence in the subpopulation. Here we have
focused on disease status at a fixed point in time. When subjects are observed over time, the time
dimension may make things more challenging especially if there is censoring. How to incorporate
the time dependence in a survival analysis setting requires further investigation.
So far we have assumed exact knowledge of the disease prevalence in the population or subpop-
ulations. This is rarely true in real life. In practice, we obtain disease prevalence from the literature
or estimate it from some pilot study. Sensitivity analyses that employ a range of plausible prevalence
values should always be performed. In a more complicated two-phase design, disease prevalence
estimated from the phase-one random sample could be used when we estimate the predictiveness
curve using the phase-two case-control sample. Plugging in a prevalence estimate introduces extra
variation in the predictiveness curve estimator which needs to accounted for in making inference.
Further research in this regard is warranted.
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